Chemotype Evolution (CE) is a discovery technology that evolves drug molecules to fit a specific target protein through successive iterations of library synthesis and screening.
CE enabled the exploration of unprecedented chemical diversity in a target-specific manner, and eventually led to the identification of proprietary incretin modulators that form the key assets in our pipeline. Three of these modulators have advanced into human clinical trials and are being evaluated for safety and efficacy in overweight or obese adults with and without diabetes.
Using Chemotype Evolution, we gain insights into target function and potential new drug leads, making it possible to design compounds for challenging and impactful targets. CE made it possible to synthesize and test hundreds of thousands of peptide fragment hybrids (Pefhtides) in a relatively short period of time. Pefhtides can have functional properties that are not achieved with natural or traditional non-natural amino acids. Carmot applied this concept to discover novel modulators of the incretin hormone receptors, glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), for the potential treatment of metabolic diseases.